Therapeutic Targeting of NSD2 in Lung Adenocarcinoma
NSD2 在肺腺癌中的治疗靶向
基本信息
- 批准号:10657069
- 负责人:
- 金额:$ 66.86万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-06-01 至 2028-05-31
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAdverse eventBiochemicalCRISPR interferenceCancer EtiologyCancer ModelCellsCessation of lifeChromatinClinicalCombined Modality TherapyDNA methylation profilingDiseaseDoseDrug TargetingDrug resistanceDrug toxicityEnzymesEpigenetic ProcessEpitopesEvolutionFutureGene ExpressionGenetic ModelsGoalsHeterogeneityHistologicHistonesImmunotherapyKRAS2 geneKRASG12DLung AdenocarcinomaLysineMAP Kinase GeneMAP2K1 geneMalignant - descriptorMalignant NeoplasmsMalignant neoplasm of lungMammalian CellMeasuresMedicineMethylationMethyltransferaseModelingMolecularMusMutationNeoplasm MetastasisOncogenicOutcomeOutputPathogenesisPathogenicityPathologicPathway interactionsPatientsPre-Clinical ModelPrognosisProteinsRegulationReportingResistance developmentResolutionRoleSignal TransductionSystemTechnologyTestingTherapeuticTreatment EfficacyTreatment outcomeUnited StatesUp-RegulationWorkXenograft procedureclinical prognosisclinically actionablecombatefficacy testingexperimental studyhuman modelimmune checkpoint blockadeimprovedin vivoinhibitorinsightinterestlung cancer cellmortalitymouse modelmultiple omicsmutantnanomolarneoplastic cellnovelpre-clinicalprogramssmall molecule inhibitorstandard of caretargeted treatmenttherapeutic targettranscriptomic profilingtranslational studytumortumor growthtumor heterogeneitytumor progression
项目摘要
ABSTRACT
Our overarching goal is to evaluate the therapeutic potential and mechanism-of-action of the epigenetic
regulatory factor NSD2 in lung adenocarcinoma (LUAD). Lung cancer is the most common cause of cancer-
related mortality in the United States and worldwide, leading to over a 1.8 million deaths each year. LUAD is its
most common histological type of lung cancer. While new targeted and immunotherapies have improved median
survival for LUAD patients, unfortunately, improvement in outcomes over the past 20 years has been
incremental. Thus, there is great interest in identifying novel factors that might cooperate with the canonical
oncogenic pathways that drive LUAD with the notion that a therapeutic strategy hitting multiple pathways will
mitigate potential drug toxicity by lowering the overall dose needed for each medicine and in parallel combat
resistance development. A central hypothesis to be tested here is that the clinically actionable and histone lysine
36 (H3K36) di-methyltransferase enzyme NSD2 is such a factor. In preliminary work we found that NSD2
promotes aggressive malignant tumor progression and rapid lethality in a classis LUAD mouse model. In our
proposal, we will investigate the molecular, epigenetic, cellular, and in vivo role of NSD2-H3K36me2 axis in lung
cancer and directly test the efficacy of NSD2-targeted therapy using a first-in-class NSD2 inhibitor and state-of-
the-art pre-clinical models of LUAD.
In Aim 1 we investigate the role of NSD2 in lung cancer pathogenesis. We have developed a KRASG12C-
driven NSD2 tunable mouse lung cancer model to investigate the function and mechanism of action of elevated
or depleted NSD2 activity in LUAD initiation, progression, metastasis, and intratumoral heterogeneity. In Aim 2
we evaluate therapeutic efficacy of NSD2 inhibition using a first-in-class potent inhibitor of NSD2. We will utilize
genetic models such as LUAD driven by KRASG12C mutations and multiple patient derived LUAD xenografts to
test anti-tumor efficacy of NSD2 inhibition as a single agent and as part of combination therapies. Together, this
work will be the first to evaluate the therapeutic potential and mechanism-of-action of NSD2 in LUAD.
摘要
我们的首要目标是评估表观遗传学的治疗潜力和作用机制。
调节因子NSD2在肺腺癌中的作用肺癌是最常见的癌症原因--
在美国和世界范围内,每年有180多万人死于相关死亡。LUAD是其
最常见的肺癌组织学类型。虽然新的靶向和免疫疗法改善了中位数
不幸的是,LUAD患者的存活率在过去20年中得到了改善
递增的。因此,人们对确定可能与规范的
推动LUAD的致癌途径,认为一种治疗策略打击多条途径将
通过降低每种药物所需的总剂量和并行作战来减轻潜在的药物毒性
抗药性的发展。这里要检验的一个中心假设是,临床上可操作的组蛋白赖氨酸
36(H3K36)二甲基转移酶NSD2就是这样一个因子。在前期工作中,我们发现NSD2
在Classsis LUAD小鼠模型中促进侵袭性恶性肿瘤的进展和快速致死性。在我们的
建议,我们将研究NSD2-H3K36me2轴在肺中的分子、表观遗传学、细胞和体内作用
并使用一流的NSD2抑制剂和最新状态直接测试NSD2靶向治疗的疗效
LUAD最先进的临床前模型。
目的1研究NSD2在肺癌发病机制中的作用。我们已经开发出KRASG12C-
驱动NSD2可调小鼠肺癌模型研究升压素的功能及作用机制
或在LUAD的启动、进展、转移和肿瘤内异质性中NSD2活性减弱。在AIM 2
我们使用一种一流的有效的NSD2抑制剂来评估抑制NSD2的治疗效果。我们将利用
遗传模型,如由KRASG12C突变驱动的LUAD和多个患者来源的LUAD异种移植
作为单一药物和联合治疗的一部分,测试NSD2抑制的抗肿瘤效果。总而言之,这
这项工作将是第一次评估NSD2在LUAD中的治疗潜力和作用机制。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Or P. Gozani其他文献
Or P. Gozani的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Or P. Gozani', 18)}}的其他基金
Role of NSD3 in regulation of cancer pathogenesis
NSD3 在癌症发病机制调节中的作用
- 批准号:
10633579 - 财政年份:2023
- 资助金额:
$ 66.86万 - 项目类别:
Function of Protein Methylation in Chromatin and Signaling Regulation
蛋白质甲基化在染色质中的功能和信号传导调控
- 批准号:
10339323 - 财政年份:2021
- 资助金额:
$ 66.86万 - 项目类别:
Function of Protein Methylation in Chromatin and Signaling Regulation
蛋白质甲基化在染色质中的功能和信号传导调控
- 批准号:
10580699 - 财政年份:2021
- 资助金额:
$ 66.86万 - 项目类别:
Role of the METTL13 Lysine Methyltransferase in Signaling and Cancer
METTL13 赖氨酸甲基转移酶在信号传导和癌症中的作用
- 批准号:
9761687 - 财政年份:2019
- 资助金额:
$ 66.86万 - 项目类别:
Unnatural Amino Acid Chemistry for Lysine Methyltransferase Substrate Discovery
赖氨酸甲基转移酶底物发现的非天然氨基酸化学
- 批准号:
9808782 - 财政年份:2019
- 资助金额:
$ 66.86万 - 项目类别:
Unnatural Amino Acid Chemistry for Lysine Methyltransferase Substrate Discovery
赖氨酸甲基转移酶底物发现的非天然氨基酸化学
- 批准号:
10006583 - 财政年份:2019
- 资助金额:
$ 66.86万 - 项目类别:
Role of the METTL13 Lysine Methyltransferase in Signaling and Cancer
METTL13 赖氨酸甲基转移酶在信号传导和癌症中的作用
- 批准号:
10569626 - 财政年份:2019
- 资助金额:
$ 66.86万 - 项目类别:
Role of the METTL13 Lysine Methyltransferase in Signaling and Cancer
METTL13 赖氨酸甲基转移酶在信号传导和癌症中的作用
- 批准号:
10338153 - 财政年份:2019
- 资助金额:
$ 66.86万 - 项目类别:
Role of the METTL13 Lysine Methyltransferase in Signaling and Cancer
METTL13 赖氨酸甲基转移酶在信号传导和癌症中的作用
- 批准号:
10116173 - 财政年份:2019
- 资助金额:
$ 66.86万 - 项目类别:
Regulation of Signaling by Histidine Protein Methylation
组氨酸蛋白甲基化对信号传导的调节
- 批准号:
9974541 - 财政年份:2019
- 资助金额:
$ 66.86万 - 项目类别:
相似海外基金
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10707830 - 财政年份:2023
- 资助金额:
$ 66.86万 - 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
- 批准号:
479728 - 财政年份:2023
- 资助金额:
$ 66.86万 - 项目类别:
Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
- 批准号:
10884567 - 财政年份:2023
- 资助金额:
$ 66.86万 - 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
- 批准号:
10751964 - 财政年份:2023
- 资助金额:
$ 66.86万 - 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
- 批准号:
486321 - 财政年份:2022
- 资助金额:
$ 66.86万 - 项目类别:
Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10676786 - 财政年份:2022
- 资助金额:
$ 66.86万 - 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10440970 - 财政年份:2022
- 资助金额:
$ 66.86万 - 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
- 批准号:
10642998 - 财政年份:2022
- 资助金额:
$ 66.86万 - 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10482465 - 财政年份:2022
- 资助金额:
$ 66.86万 - 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
- 批准号:
10191053 - 财政年份:2020
- 资助金额:
$ 66.86万 - 项目类别: